Medijane Hldgs Inc (OTC:MJMD)

The SEC stepping up pace of probe into marijuana stocks. Investors should be concerned about pump campaign financed by undisclosed shareholder(s) holding larger amount of MJMD stock they intend to sell; Shareholder who owns(ed) 15 million shares of MJMD has been fined by SEC for unregistered stock sales in a shell company he owned that the SEC claimed was part of a pump and dump; Shareholder who owns 7 million shares was just fined $8 million by FNRA for “anti-money laundering failures” involving $850 million in penny stock transactions; Chairman of board is director of company that received 26 million shares of MJMD per an exclusive licensing agreement; It appears MJMD omits relationship between itself and a company that the Chairman is a director of that aims to raise capital to fund marijuana investment.

Please see our full report here.

LONGMONT, CO--(Marketwired - Mar 21, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that it has entered into a License Agreement with Phoenix Bio Pharmaceuticals Corporation ("Phoenix Bio Pharm"), a Colorado-based developer of medicinal cannabinoid products and delivery systems for the treatment and management of illnesses.

As per terms of the License Agreement, MediJane has acquired an exclusive North American license for all intellectual property, processes, and expertise related to certain medicinal cannabinoid products and delivery systems developed by Phoenix Bio Pharm and its team. 

Medicinal cannabis products falling under the License Agreement include transdermal patches, orally administered extracts, concentrated extracts for vaporizers and inhalers, sublingual and buccal dispensing products and extraction technology, suppository delivery systems, salves, creams, gels, lotions, and liquid extracts, and any products or active ingredients sources through Phoenix Bio Pharm affiliates or third party suppliers or licensors. The Company will also have the right to sublicense the rights and to utilize Phoenix Bio Pharm copyrights for marketing and distribution purposes.

In consideration of the license, the Company issued 26,000,000 restricted shares of its common stock to Phoenix Bio Pharm. These shares were issued pursuant to an exemption from registration relying on the exemption from registration provided for under Rule 506 of Regulation D, promulgated under the United States Securities Act of 1933, as amended.

"We are extremely excited to have completed the acquisition of the exclusive North American rights to Phoenix Bio Pharmaceuticals' innovative medicinal marijuana products and delivery system technologies," commented Ronald Lusk, President of MediJane Holdings Inc. "The market potential for medicinal marijuana products utilizing these new technologies is absolutely enormous and I look forward to implementing our growth strategy and ramping up our marketing efforts in the very near future."